Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Bausch + Lomb to buy ‘dry eye’ treatment from Novartis in a $2.5 billion deal By: MarketWatch June 30, 2023 at 10:30 AM EDT Bausch + Lomb's stock leapt Friday, after the eye-health products company announced a $2.5 billion deal to buy Novartis' "dry eye" treatment Xiidra. Read More >> Related Stocks: BLCO HEALTHCARE Novartis Ag ADR Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Bausch + Lomb to buy ‘dry eye’ treatment from Novartis in a $2.5 billion deal By: MarketWatch June 30, 2023 at 10:30 AM EDT Bausch + Lomb's stock leapt Friday, after the eye-health products company announced a $2.5 billion deal to buy Novartis' "dry eye" treatment Xiidra. Read More >> Related Stocks: BLCO HEALTHCARE Novartis Ag ADR